Julia M. Seller

Alicante, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain.

One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain.

Journal: ESC heart failure

Published: December 14, 2025

Heart Failure in Advanced Chronic Kidney Disease: Overlooked No More.

Heart Failure in Advanced Chronic Kidney Disease: Overlooked No More.

Journal: JACC. Heart failure

Published: April 08, 2025

β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction.

β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction.

Journal: JAMA cardiology

Published: February 07, 2024

Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status.

Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status.

Journal: JACC. Heart failure

Published: February 13, 2023

Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction.

Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction.

Journal: Journal of cardiac failure

Published: January 17, 2023

Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction.

Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction.

Journal: Revista espanola de cardiologia (English ed.)

Published: November 07, 2022

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction.

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction.

Journal: Scientific reports

Published: October 26, 2022

Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction.

Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction.

Journal: Revista espanola de cardiologia (English ed.)

Published: June 04, 2022

Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2 ): a randomized clinical trial.

Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2 ): a randomized clinical trial.

Journal: European journal of heart failure

Published: April 25, 2022

Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use.

Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use.

Journal: Reviews in cardiovascular medicine

Published: January 05, 2022

Reply: Beta-Blocker Withdrawal and Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction.

Reply: Beta-Blocker Withdrawal and Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction.

Journal: Journal of the American College of Cardiology

Published: December 28, 2021

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction.

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction.

Journal: Journal of the American College of Cardiology

Published: July 27, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026